KACTUS

KactusBio is an R&D-driven, innovative biotech company dedicated to drug discovery, immunotherapy, and mRNA vaccines.

Established in March 2018, KactusBio's growth outpaced the industry. The company has established a strategic partnership with more than 300 companies focusing on innovative antibody-drug discovery, cell & gene therapy, and mRNA vaccine development. Our R&D and production headquarters recently expanded 50,000 sqft and we have a scientific team of 150 researchers and production engineers. Our new 100,000 sqft GMP facility is scheduled to be at full output in late 2022.